New hope for lung cancer patients who failed immunotherapy?
NCT ID NCT03334617
First seen Oct 31, 2025 · Last updated May 13, 2026 · Updated 26 times
Summary
This study is for people with advanced non-small cell lung cancer whose disease got worse after treatment with immunotherapy (anti-PD-1/PD-L1 drugs). It tests several different drug combinations to see which ones might work better based on the specific features of each person's tumor. About 528 adults are taking part in this phase 2 trial, which aims to find more effective ways to control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Duarte, California, 91010, United States
-
Research Site
Fullerton, California, 92835, United States
-
Research Site
La Jolla, California, 92093, United States
-
Research Site
Los Angeles, California, 90095, United States
-
Research Site
Washington D.C., District of Columbia, 20016, United States
-
Research Site
Chicago, Illinois, 60637, United States
-
Research Site
Baltimore, Maryland, 21224, United States
-
Research Site
Baltimore, Maryland, 21287, United States
-
Research Site
Boston, Massachusetts, 02215, United States
-
Research Site
St Louis, Missouri, 63110, United States
-
Research Site
New York, New York, 10032, United States
-
Research Site
Philadelphia, Pennsylvania, 19111, United States
-
Research Site
Pittsburgh, Pennsylvania, 15232, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Nashville, Tennessee, 37212, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Fairfax, Virginia, 22031, United States
-
Research Site
Innsbruck, 6020, Austria
-
Research Site
Salzburg, 5020, Austria
-
Research Site
Vienna, 1140, Austria
-
Research Site
Vienna, 1210, Austria
-
Research Site
Edmonton, Alberta, T6G 1Z2, Canada
-
Research Site
Brampton, Ontario, L6R 3J7, Canada
-
Research Site
Ottawa, Ontario, K1H 8L6, Canada
-
Research Site
Toronto, Ontario, M5G 2M9, Canada
-
Research Site
Montreal, Quebec, H2X 3E4, Canada
-
Research Site
Bordeaux, 33076, France
-
Research Site
Nantes, 44093, France
-
Research Site
Paris, 75877, France
-
Research Site
Villejuif, 94800, France
-
Research Site
Berlin, 12203, Germany
-
Research Site
Esslingen a.N., 73730, Germany
-
Research Site
Großhansdorf, 22927, Germany
-
Research Site
Heidelberg, 69126, Germany
-
Research Site
Haifa, 31096, Israel
-
Research Site
Kfar Saba, 95847, Israel
-
Research Site
Petah Tikva, 49100, Israel
-
Research Site
Ramat Gan, 5265601, Israel
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 6351, South Korea
-
Research Site
Barcelona, 08036, Spain
-
Research Site
Madrid, 28007, Spain
-
Research Site
Madrid, 28034, Spain
-
Research Site
Seville, 41009, Spain
Conditions
Explore the condition pages connected to this study.